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ESBLs, Forever?
This publication represents the proceedings of the ESCMID Conference on Extended-spectrum Beta-
lactamases and was published without commercial support. In the publication, some declarations
concerning conﬂict of interest were not included. All declarations from all authors appear below.
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IRT and CMT b-lactamases and inhibitor resistance
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Extended-spectrum b-lactamases and the permeability barrier
L. Martı´nez-Martı´nez
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received research support from Chiron, Wyeth, GSK, MSD and Pﬁzer, and declares that he has no
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interest concerning the views expressed.
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